Login to Your Account



Other News To Note


Friday, January 28, 2011
RXi Pharmaceuticals Corp., of Worcester, Mass., reported its collaboration with miRagen Therapeutics Inc., of Boulder, Colo., demonstrated that RXi's self-delivering rxRNA (sd-rxRNA) technology could be used in vitro to enhance the activity of a microRNA of interest to miRagen.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription